BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Europabio - ECPv6.17.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.europabio.org
X-WR-CALDESC:Events for Europabio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20220615T200000
DTEND;TZID=Europe/Brussels:20220615T210000
DTSTAMP:20220510T112747Z
CREATED:20220505T095121Z
LAST-MODIFIED:20220510T112747Z
UID:4448-1655323200-1655326800@www.europabio.org
SUMMARY:EuropaBio: BIO 2022
DESCRIPTION:BIO 2022: The big bang in pharma legislation: A European epicentre shaping global healthcare and competitive industry \n\n\n\n\n\nEuropaBio is pleased to lead a panel discussion at BIO in San Diego and invites all delegates to join us to discuss the future of healthcare innovation as impacted by European changes. \n\n\n\n20 years ago\, European pharmaceutical legislation underwent a major review\, a critical point in the continent’s single market in healthcare.  Since then Europe has grown\, bringing new voices\, political momentum and advanced technologies into healthcare and today\, the European Commission is reshaping pharma legislation to meet the twin priorities of equality of access and ability to pay. \n\n\n\nThis is a significant moment for the global biopharmaceutical industry and one that will change the dynamics of investment\, science and market access for companies worldwide. \n\n\n\nHow does the legislative framework for medicines achieve its aims through reform? Balancing equity and affordability of medicines with reward for high-risk innovation from SMEs through to multi-nationals. \n\n\n\nPanel focus: \n\n\n\nThe drive for reform – the world is changing and with it must change the pathway for medicines so that all patients benefitWhat do SMEs\, mid-sized and multi-national companies need from legislation to ensure they can deliver innovation in the long term?When change is inevitable\, how does industry roll up its shelves and help collectively drive a new future\, rather than waiting for it to be imposed?How will European reform impact the global biopharma sector in a time of geopolitical realignment and regrowth?\n\n\n\n \n\n\n\n\n\n\n\n\nMore info
URL:https://www.europabio.org/event/europabio-bio-2022/
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2022/05/inline_large_bio2022-linkedin-banner.jpeg
END:VEVENT
END:VCALENDAR